Literature DB >> 23034914

Chondroitin sulfate proteoglycans in demyelinated lesions impair remyelination.

Lorraine W Lau1, Michael B Keough, Sarah Haylock-Jacobs, Rowena Cua, Axinia Döring, Scott Sloka, David P Stirling, Serge Rivest, V Wee Yong.   

Abstract

OBJECTIVE: Failure of remyelination is a critical impediment to recovery in multiple sclerosis (MS). Chondroitin sulfate proteoglycans (CSPGs) have been reported to accumulate in MS lesions, and we thus examined the functional roles of CSPGs on oligodendrocyte precursor cells (OPCs), oligodendrocytes, and remyelination.
METHODS: We evaluated the expression of CSPGs in lysolecithin-injected mouse spinal cord, an animal model of demyelination and spontaneous remyelination. The functional impact of CSPGs on OPCs and remyelination was investigated using cultured adult murine and human OPCs and by treating demyelinated mice with xyloside to reduce the CSPG deposition that occurred following injury.
RESULTS: Early and robust upregulation of CSPGs following lysolecithin-induced demyelination was cleared during remyelination. In culture, CSPGs anchored onto the substratum reduced the adhesion of mouse and human OPCs and their subsequent morphological differentiation into process-bearing oligodendrocytes. Soluble CSPGs added to already adherent OPCs reduced the development of processes, whereas the acquisition of mature myelin proteins was unimpeded. Stripe assays of alternating CSPG and control substrata confirmed the nonpermissive nature of CSPGs for OPC adhesion and morphological differentiation. Enzymatic degradation of CSPGs with chondroitinase ABC was sufficient to overcome CSPG-dependent inhibition of human oligodendrocytes. Finally, in vivo xyloside treatment to reduce CSPG synthesis in lysolecithin-demyelinated mice increased numbers of OPCs and oligodendrocytes in lesions, and culminated in improved remyelination.
INTERPRETATION: These results identify CSPGs as a nonpermissive substrate for OPCs and oligodendrocytes, and as a prominent impediment to remyelination. The data suggest the requirement for the neutralization of CSPGs for repair after demyelination.
Copyright © 2012 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23034914     DOI: 10.1002/ana.23599

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  99 in total

Review 1.  Microenvironmental regulation of oligodendrocyte replacement and remyelination in spinal cord injury.

Authors:  Arsalan Alizadeh; Soheila Karimi-Abdolrezaee
Journal:  J Physiol       Date:  2016-03-29       Impact factor: 5.182

Review 2.  Pathophysiology of the brain extracellular matrix: a new target for remyelination.

Authors:  Lorraine W Lau; Rowena Cua; Michael B Keough; Sarah Haylock-Jacobs; V Wee Yong
Journal:  Nat Rev Neurosci       Date:  2013-08-29       Impact factor: 34.870

3.  Inhibitors of myelination: ECM changes, CSPGs and PTPs.

Authors:  Danielle E Harlow; Wendy B Macklin
Journal:  Exp Neurol       Date:  2013-11-04       Impact factor: 5.330

4.  The active contribution of OPCs to neuroinflammation is mediated by LRP1.

Authors:  Anthony Fernández-Castañeda; Megan S Chappell; Dorian A Rosen; Scott M Seki; Rebecca M Beiter; David M Johanson; Delaney Liskey; Emily Farber; Suna Onengut-Gumuscu; Christopher C Overall; Jeffrey L Dupree; Alban Gaultier
Journal:  Acta Neuropathol       Date:  2019-09-24       Impact factor: 17.088

Review 5.  The benefits of neuroinflammation for the repair of the injured central nervous system.

Authors:  Heather Y F Yong; Khalil S Rawji; Samira Ghorbani; Mengzhou Xue; V Wee Yong
Journal:  Cell Mol Immunol       Date:  2019-03-15       Impact factor: 11.530

Review 6.  Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic.

Authors:  Sha Mi; R Blake Pepinsky; Diego Cadavid
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

Review 7.  Scar-modulating treatments for central nervous system injury.

Authors:  Dingding Shen; Xiaodong Wang; Xiaosong Gu
Journal:  Neurosci Bull       Date:  2014-06-24       Impact factor: 5.203

8.  2-Arachidonoylglycerol Reduces Proteoglycans and Enhances Remyelination in a Progressive Model of Demyelination.

Authors:  Ana Feliú; Itziar Bonilla Del Río; Francisco Javier Carrillo-Salinas; Gloria Hernández-Torres; Leyre Mestre; Nagore Puente; Silvia Ortega-Gutiérrez; Maria L López-Rodríguez; Pedro Grandes; Miriam Mecha; Carmen Guaza
Journal:  J Neurosci       Date:  2017-07-27       Impact factor: 6.167

9.  Role of Chondroitin Sulfate (CS) Modification in the Regulation of Protein-tyrosine Phosphatase Receptor Type Z (PTPRZ) Activity: PLEIOTROPHIN-PTPRZ-A SIGNALING IS INVOLVED IN OLIGODENDROCYTE DIFFERENTIATION.

Authors:  Kazuya Kuboyama; Akihiro Fujikawa; Ryoko Suzuki; Naomi Tanga; Masaharu Noda
Journal:  J Biol Chem       Date:  2016-07-21       Impact factor: 5.157

Review 10.  Remyelination therapy for multiple sclerosis.

Authors:  Michael B Keough; V Wee Yong
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.